POINT logo light blue (png).png
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
13 nov. 2023 07h30 HE | POINT Biopharma
INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT logo light blue (png).png
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
18 sept. 2023 08h00 HE | POINT Biopharma
INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery,...
POINT logo light blue (png).png
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
14 août 2023 07h30 HE | POINT Biopharma
Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first...
POINT logo light blue (png).png
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
31 juil. 2023 09h00 HE | POINT Biopharma
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc....
POINT logo light blue (png).png
POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress
26 juin 2023 07h30 HE | POINT Biopharma
Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555...
POINT logo light blue (png).png
POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors
12 juin 2023 08h00 HE | POINT Biopharma
INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT logo light blue (png).png
POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
07 juin 2023 07h00 HE | POINT Biopharma
Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023 INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”),...
POINT logo light blue (png).png
POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
15 mai 2023 07h30 HE | POINT Biopharma
U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April 2023 Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer,...
POINT logo light blue (png).png
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
24 avr. 2023 07h30 HE | POINT Biopharma; Lantheus Holdings, Inc.
BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
POINT logo light blue (png).png
Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
04 avr. 2023 08h00 HE | POINT Biopharma
BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an...